MindRank AI Recognized in Dual Honors: Named to ScienceAI Top 10 and Yangtze River Delta Digital Health Innovation Leaders
MindRank
AI Drug Developer
Recently, as multiple annual awards and research results have been released successively, MindRank has once again received significant accolades in the artificial intelligence and digital healthcare sectors for its outstanding achievements in AI-driven innovative drug development.
Top 10 ScienceAI Leading Enterprises 2024
On December 27, 2024, the Machine Heart 2024 Annual AI List was announced, and "MindRank" was selected again.“Top 10 Leading Enterprises in ScienceAI.
As a leading artificial intelligence information service platform in China, the Machine Heart "AI China" Annual Awards, since its release in 2017, has been held consecutively for 7 sessions, witnessing every significant interaction and advancement in artificial intelligence within the industry, and has becomeThe wind vane of the development of artificial intelligence technology and industry,Maintain a leading position in the industry in terms of professionalism, influence, and authority.
The selection of the TOP 10 leading enterprises in ScienceAI requires companies to focus on the intersection of artificial intelligence with other disciplines and related industries. It aims to promote the development of related industries by solving scientific problems, while possessing groundbreaking research achievements and strong AI technology capabilities, with clear application scenarios and having formed relatively mature products and solutions.
Original link:
Settling·Still Waters Run Deep —— Machine Heart 2024 Annual AI List Revealed
Top 20 Pioneers of Digital Healthcare Innovation in the Yangtze River Delta
On December 27, 2024, the unveiling ceremony of the Yangtze River Delta Biomedical New Quality Leading List, jointly initiated by the G60 Sci-Tech Innovation Corridor Innovation Research Center of the Yangtze River Delta, the national biomedical enterprises platform, and YiYun Technology, was held in Suzhou. MindRank was selected."Top 20 Innovators in Digital Healthcare."
The Yangtze River Delta Biomedical New Quality Leadership List is divided into three major categories for evaluation: biomedicine, medical devices, and digital healthcare. Based on the quantitative growth evaluation standards for enterprises refined over the years by the Huayi Research Institute, and combined with processes such as enterprise registration, interview research, enterprise review, and report writing, the shortlisted enterprises are comprehensively evaluated by a professional review committee on aspects like financials, operational data, innovation capability, investor returns, and social responsibility, forming an objective third-party industry evaluation list.
Original link:
As a representative company in China's AI pharmaceuticals field, "MindRank" is continuously developing a series of new drug pipelines with the potential to be first-in-class or best-in-class. By utilizing the team's self-developed, world-leading, industrial-grade, one-stop AI-driven innovative drug discovery platform,MindRank's self-developed GLP-1RA small molecule oral drug MDR-001 is currently proceeding smoothly in Phase IIb clinical trials.Multiple innovative drugs in the oncology and metabolic fields have entered the IND-Enabling study stage. AI-powered drug discovery technologies, such as small molecules, molecular glues, and PROTAC, have been continuously implemented and optimized in internal and external collaboration projects, significantly accelerating the development of innovative drugs.
About MindRank
MindRank is a clinical-stage AI-driven innovative drug discovery company. The company’s vision is to continuously deliver differentiated and high-clinical-value drug candidates by promoting the integration of various cutting-edge technologies in artificial intelligence and novel drug development, thereby helping more lives regain health.
MindRank's AI pharmaceutical solutions were rated as one of the "11 most important AI drug R&D breakthrough achievements globally from 2018-2020" by the authoritative European and American institution Deep Pharma Intelligence. In 2023, it was included in Forbes' "Forbes Asia 100 to Watch" list, with only 11 start-up companies from mainland China making the list. In 2024, it was selected for Fortune magazine's IMPACT Enterprise List as one of "China's most socially influential start-up companies."
Related Reading:
MindRank Selected as One of the Top 100 Companies to Watch in the 2023 Forbes Asia-Pacific Region
For more information, please visit the website: www.mindrank.ai
Cooperation: bd@mindrank.ai
Other: info@mindrank.ai